Ikarian Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Ikarian Capital’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-217,915	Closed	-$6.98M	–	228
2022 Q1	$6.98M	Sell	217,915 -351,114	-62%	-$10.1M	0.92%	31
2021 Q4	$12.4M	Sell	569,029 -4,351	-0.8%	-$95.9K	1.84%	14
2021 Q3	$12.6M	Buy	573,380 +28,378	+5%	+$568K	0.89%	28
2021 Q2	$10.6M	Buy	545,002 +99,814	+22%	+$1.81M	0.86%	32
2021 Q1	$7.67M	Buy	445,188 +126,298	+40%	+$2M	0.26%	84
2020 Q4	$5.11M	Buy	318,890 +5,000	+2%	+$69.4K	0.23%	93
2020 Q3	$3.35M	Buy	313,890 +304,232	+3,150%	+$3.62M	0.24%	86
2020 Q2	$118K	Buy	+9,658	New	+$120K	0.01%	152
2020 Q1	–	Sell	-9,660	Closed	-$132K	–	189
2019 Q4	$132K	Buy	+9,660	New	+$126K	0.02%	100

Other funds holding SRRA

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ikarian Capital's SRRA Position: Q2 2022 in Review

Ikarian Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 217,915 shares — an estimated $6.98M sold.

Ikarian Capital first reported a position in SRRA in Q4 2019 and held it in 9 quarters. The position peaked at $12.6M in Q3 2021. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

Ikarian Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 217,915 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $6.98M.
Ikarian Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Ikarian Capital's Sierra Oncology, Inc. Common Stock position peaked at $12.6M in Q3 2021.
109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.